Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Evolution of the BRCA2-associated pancreatic cancer genome with platinum-based chemotherapy
FY 2016-17
Summary
Pancreatic cancer will be the second leading cause of cancer death in North America by 2020. Most patients present with incurable disease. Despite new chemotherapies, survival rates have not improved significantly. The ineffectiveness of conventional therapies may reflect the existence of different subtypes of pancreatic cancer, which each respond differently to a given treatment. This highlights the need for personalized (precision) treatment. Recent studies have shown that pancreatic cancers are driven by various genetic mutations. This knowledge has prompted interest in the development of novel therapies targeting specific genetic mutations. 10% of pancreatic cancers are associated with an inherited genetic mutation, the most common one being the BRCA2 (BReast CAncer) gene. This gene is involved in repairing damaged DNA. In carriers of BRCA2 mutations, the inability to adequately repair DNA leads to cancer development. BRCA2-associated pancreas cancers are particularly vulnerable to drugs which target the DNA repair system. However, despite an initial response, most of these cancers eventually develop resistance to the drugs, allowing them to spread. To understand the mechanisms driving this resistance, we will analyze the genetic makeup of pancreas cancers in patients with a BRCA-2 mutation. In addition, we will implant human BRCA2-associated pancreas cancer tissue into the mouse pancreas to create a model which replicates the biology of the disease. These mice will receive a similar drug treatment, and will be observed for disease progression. We will analyze their tumours to identify DNA changes which confer resistance to treatment and enable disease spread.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367398
Name
Wang Yifan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evolution of the BRCA2-associated pancreatic cancer genome with platinum-based chemotherapy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brca2; Clonal Evolution; Homology Directed Repair; Mutational Signature; Orthotopic Implantation; Pancreatic Cancer; Patient-Derived Xenograft; Platinum-Based Chemotherapy; Targeted Therapy
Abstract
Pancreatic cancer will be the second leading cause of cancer death in North America by 2020. Most patients present with incurable disease. Despite new chemotherapies, survival rates have not improved significantly. The ineffectiveness of conventional therapies may reflect the existence of different subtypes of pancreatic cancer, which each respond differently to a given treatment. This highlights the need for personalized (precision) treatment. Recent studies have shown that pancreatic cancers are driven by various genetic mutations. This knowledge has prompted interest in the development of novel therapies targeting specific genetic mutations. 10% of pancreatic cancers are associated with an inherited genetic mutation, the most common one being the BRCA2 (BReast CAncer) gene. This gene is involved in repairing damaged DNA. In carriers of BRCA2 mutations, the inability to adequately repair DNA leads to cancer development. BRCA2-associated pancreas cancers are particularly vulnerable to drugs which target the DNA repair system. However, despite an initial response, most of these cancers eventually develop resistance to the drugs, allowing them to spread. To understand the mechanisms driving this resistance, we will analyze the genetic makeup of pancreas cancers in patients with a BRCA-2 mutation. In addition, we will implant human BRCA2-associated pancreas cancer tissue into the mouse pancreas to create a model which replicates the biology of the disease. These mice will receive a similar drug treatment, and will be observed for disease progression. We will analyze their tumours to identify DNA changes which confer resistance to treatment and enable disease spread.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Yifan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~